Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
News|Articles|October 6, 2025
7 Endocrinology Headlines You Missed in September 2025
Author(s)Ryan Livingston
Fact checked by: Abigail Brooks, MA
Catch up on FDA decisions, critical trial results, and expert perspectives on endocrinology.
Advertisement
Advertisement
From advances in
Related to this article
Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.
Presented at EASD 2026, the present analysis discusses CBL-514’s apparent efficacy in reducing L2-L3 visceral fat compared to placebo.
Ryaltris pediatric approval, lonvo-z and deucrictibant HAE filings, PVX108 Fast Track, and Palforzia's exit headline Q3 2026 allergy news.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
The FDA set a June 18, 2027, PDUFA date for the subcutaneous GP IIb/IIIa inhibitor, based on phase 3 CeleBrate data.
Advertisement
Advertisement